Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial Amit Arjyal, MBBS, Dr Buddha Basnyat, MD, Samir Koirala, MBBS, Abhilasha Karkey, MSc, Sabina Dongol, MSc, Krishna Kumar Agrawaal, MBBS, Nikki Shakya, MBBS, Kabina Shrestha, MBBS, Manish Sharma, MD, Sanju Lama, MBBS, Kasturi Shrestha, MD, Nely Shrestha Khatri, MBBS, Umesh Shrestha, MBBS, James I Campbell, MIBMS, Stephen Baker, PhD, Jeremy Farrar, FRCP, Marcel Wolbers, PhD, Christiane Dolecek, MD The Lancet Infectious Diseases Volume 11, Issue 6, Pages 445-454 (June 2011) DOI: 10.1016/S1473-3099(11)70089-5 Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile *Two culture-positive patients in both the chloramphenicol and glatifloxacin groups were lost to follow-up before day 8. The Lancet Infectious Diseases 2011 11, 445-454DOI: (10.1016/S1473-3099(11)70089-5) Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 2 Kaplan-Meier estimates for time to treatment failure, fever clearance, and relapse for culture-positive patients The Lancet Infectious Diseases 2011 11, 445-454DOI: (10.1016/S1473-3099(11)70089-5) Copyright © 2011 Elsevier Ltd Terms and Conditions